The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy

Multiple tumors have responded well to immunotherapies, which use monoclonal antibodies to block the immune checkpoint proteins and reactivate the T-cell immune response to cancer cells. Significantly, the anti-PD-1 antibodies pembrolizumab and nivolumab, which were approved in 2014, have revolution...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Tae-Jun, Lee, Hyun-Tae, Gu, Nahyeon, Jang, Yu-Jeong, Choi, Seung-Beom, Park, Ui-Beom, Lee, Sang-Hyung, Heo, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775377/
https://www.ncbi.nlm.nih.gov/pubmed/36551910
http://dx.doi.org/10.3390/biomedicines10123154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775377/
https://www.ncbi.nlm.nih.gov/pubmed/36551910
http://dx.doi.org/10.3390/biomedicines10123154

Ejemplares similares